PDCD1 and neoplasm: A recent study identified that in combination with STM2457, a highly potent and selective catalytic inhibitor of METTL3, anti-PD1 treatment resulted in a remarkable anti-tumor effect compared with that of the individual treatments in CRC mouse models through the increased infiltration of activated T cells (156).